Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
about
Trastuzumab containing regimens for early breast cancerCardiac toxicity of trastuzumab in elderly patients with breast cancerAdjuvant systemic therapy in older women with breast cancerPathophysiology and preventive strategies of anthracycline-induced cardiotoxicityInfracentimetric HER-2 positive breast tumours-review of the literatureHow Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast CancerAdjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and ManagementTreatment of early-stage HER2+ breast cancer-an evolving fieldCardiac risk in the treatment of breast cancer: assessment and management.Long term side effects of adjuvant chemotherapy in patients with early breast cancerSystemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineMechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage.The impact of comorbidity on Health-Related Quality of Life among cancer survivors: analyses of data from the PROFILES registry.Relationship between clinical data and gene expression in the HER2/ErbB2-dependent signaling pathway in patients with acute heart failure.Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data.Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors.Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.Both aerobic exercise and resveratrol supplementation attenuate doxorubicin-induced cardiac injury in mice.Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclinesOptimizing the management of HER2-positive early breast cancer: the clinical reality.HER2 status and breast cancer therapy: recent advances.Translating research into evidence-based practice: the National Cancer Institute Community Clinical Oncology ProgramPopulation pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity.Targeting HER2 in breast cancer: overview of long-term experienceHER2 signaling pathway and trastuzumab cardiotoxicity.Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.Cardiovascular toxicities from systemic breast cancer therapy.Risk of trastuzumab-related cardiotoxicity in early breast cancer patients: a prospective observational study.Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patientsCardiac dysfunction after cancer treatment.Adjuvant therapy for women over age 65 with breast cancerPharmacoeconomic considerations in the treatment of breast cancer.Optimal systemic therapy for early breast cancer in women: a clinical practice guidelineGeriatric assessment in older patients with breast cancer.Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to consider
P2860
Q24200192-3DF7C2F2-B00D-4ED9-8D36-7FF19AEB8ED1Q26741182-8704DBE9-C5CB-476D-94CD-377788788E60Q26741523-B192C015-93BC-41B5-9C1C-1DFD19721497Q26744675-B133D26B-192C-4273-AE41-C202F6093833Q26774597-643C399C-12B2-453D-B7B2-F272B41429E1Q26824542-2E39F1FE-FFEF-421A-A94C-A651A82CE943Q27025860-9E02AABD-774A-4248-B741-8F3087C7BFBDQ28068290-001D37D5-2942-4EA2-9C74-3239DC25CDA7Q28081124-F6FA1114-A971-4B9F-98AC-965AA984EC55Q28081385-D64C22AC-14B0-44E8-A89E-0154933BA5A3Q28083233-539FFF87-63EB-4967-A230-809D55B958C1Q28260063-16CF5AB8-8B0A-423D-943F-2C75AB53B91DQ30439608-A7BDD94A-6AEF-4CD7-B824-6111D5CD9D37Q30659496-7F0F05C4-A4A8-4676-8D1F-C05766A760EDQ30663382-96EAB92C-2101-4AA4-BF7D-F811CDC2E3FCQ31004660-81FD1DD8-6FEB-41C3-8547-B69ED772CA48Q33427353-41622120-87D2-4AEA-BB32-44CDA9ADA6A9Q33862786-8043FE38-5269-43BD-A522-8EA8F2B1EDAEQ33930241-96245AF5-D573-4E36-A10D-7A9FEC380B0FQ33949465-ACA14CF3-7D53-487D-B056-60A9B5A78F1AQ33964848-C3C1911B-C2F8-4AD3-AA7E-E111744B60EEQ33976440-DE0DDF16-8A7B-4382-8112-C96DCC82574CQ34023749-28A9324A-32DD-45FD-B7A2-C1FC0013D472Q34035460-0EDC87BA-3A76-44DF-A349-75AE59FC3E66Q34062418-7A17C246-8955-4B10-8799-2006EB1FAE42Q34155601-0A82734B-9028-4278-995F-CF570427D6B3Q34189102-537CF5AF-07BE-4B6C-AA8D-7D356B756BBDQ34272044-4441A41B-2563-429B-BF91-6C7B378A00FCQ34328064-BE7618A7-6F11-4376-B743-140C5E7CD6FCQ34484185-3267E824-976C-440C-A6B3-9D6E2A36D7C8Q34630349-1FDD651C-46C0-49DE-9396-4317E2CCCDBAQ34779675-CBE7872C-BAE0-4F8F-A728-3F60580D7B04Q34975825-D5DC81A4-3F2B-4D3E-9FE7-9118706B7B17Q35039549-2635A87B-49EC-44D0-8B35-7B1FCFEC626DQ35051256-4C270156-8E5D-4BAE-B0AB-2C03D7B22689Q35205385-0663992F-63EA-40F3-9CB4-84043D9FDF6FQ35239634-D962D68D-3AC7-4FCB-8039-5E196B4341C2Q35428376-13AC8C58-00F8-4A67-95AF-DE0205EA9899Q35490056-110A2849-661F-438D-9663-02F47387C16DQ35583779-5860720B-18DF-45C8-A567-3C3A40CA13DA
P2860
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Cardiac safety analysis of dox ...... adjuvant breast cancer trial.
@ast
Cardiac safety analysis of dox ...... adjuvant breast cancer trial.
@en
type
label
Cardiac safety analysis of dox ...... adjuvant breast cancer trial.
@ast
Cardiac safety analysis of dox ...... adjuvant breast cancer trial.
@en
prefLabel
Cardiac safety analysis of dox ...... adjuvant breast cancer trial.
@ast
Cardiac safety analysis of dox ...... adjuvant breast cancer trial.
@en
P2093
P2860
P356
P1476
Cardiac safety analysis of dox ...... adjuvant breast cancer trial.
@en
P2093
Allan S Jaffe
Bernard J Gersh
Clifford A Hudis
Edith A Perez
Eric P Winer
George W Sledge
James N Ingle
Julie R Gralow
Karen A Gelmon
Nancy E Davidson
P2860
P304
P356
10.1200/JCO.2007.13.5467
P407
P577
2008-02-04T00:00:00Z